Cailin Conner

Cailin Conner is a contributing writer for DocWire News with experience covering scientific and medical news.

Articles by Cailin Conner

Cailin ConnerColorectal Cancer | October 20, 2024
A study reported a steady increase in early-onset colorectal cancer cases.
Read More
Cailin ConnerChronic Spontaneous Urticaria | October 15, 2024
Urticaria raises the risk of ADHD, bipolar disorder, and schizophrenia.
Cailin ConnerColorectal Cancer | October 14, 2024
Colorectal cancer screening uptake among privately insured individuals aged 45-49 years have increased significantly.
Cailin ConnerColorectal Cancer | October 9, 2024
Colorectal cancer patients with Medicaid or no insurance face significantly higher risks for surgery and other complications.
Cailin ConnerColorectal Cancer | October 7, 2024
A recurrence-free survival period of 8 months is a crucial cutoff for early recurrence.
Cailin ConnerChronic Spontaneous Urticaria | October 3, 2024
Omalizumab is a safe and effective long-term treatment for CSU.
Cailin ConnerColorectal Cancer | September 25, 2024
Researchers found that food antigens, particularly milk proteins, activate the intestinal immune system to suppress tumors.
Cailin ConnerColorectal Cancer | September 24, 2024
A study found that metabolites from diets high in red and processed meat significantly increase the risk of young-onset CRC.
Cailin ConnerColorectal Cancer | September 23, 2024
Laparoscopic colectomy in obese patients with locally advanced colon cancer offers comparable long-term outcomes to open surg
Cailin ConnerChronic Spontaneous Urticaria | September 18, 2024
Nearly 50% of patients with chronic spontaneous urticaria are atopic, with atopy linked to increased risk of dermatographism,
Cailin ConnerChronic Spontaneous Urticaria | September 17, 2024
A recent study demonstrated significant associations between acute urticaria and cardiovascular comorbidities.
Cailin ConnerChronic Spontaneous Urticaria | September 18, 2024
Autoimmune mast cell activation test shows promise as a diagnostic tool for chronic spontaneous urticaria.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
Omalizumab treatment in CSU patients leads to significant changes in T-cell subpopulations.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
Patients with both asthma and chronic urticaria have more severe allergic responses.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
Omalizumab effectively reduces symptoms in CSU patients, but a 300 mg dose is recommended.
Cailin ConnerChronic Spontaneous Urticaria | September 9, 2024
A systematic review found that biologic omalizumab is cost-effective for treating H1 antihistamine–refractory CSU.
Cailin ConnerMultiple Myeloma | September 5, 2024
Significant delays in diagnosing multiple myeloma exist.
Cailin ConnerDiabetes | September 18, 2024
Very high HDL cholesterol levels are associated with a 38% increased risk of heart disease in patients with diabetes.
Cailin ConnerMultiple Myeloma | September 3, 2024
Talquetamab is a promising treatment for relapsed multiple myeloma, however, it presents unique side effects.
Cailin ConnerMultiple Myeloma | September 1, 2024
In MM patients, prescription delays were linked to Black race, older age, inpatient diagnosis, and severe renal impairment.